A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies

Journal of Infectious Diseases

Volumn 205, Issue 1, 2012, Pages 28-34

  Fritz, Richard ^a   Sabarth, Nicolas ^a   Kiermayr, Stefan ^a   Hohenadl, Christine ^a   Howard, M Keith ^a   Ilk, Reinhard ^a   Kistner, Otfried ^a   Ehrlich, Hartmut J ^a   Barrett, P Noel ^a   Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEURAMINIDASE INHIBITING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFLUENZA A (H5N1); INFLUENZA VACCINATION; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL INFLUENZA; SEROCONVERSION; SINGLE DRUG DOSE; VACCINE PRODUCTION; VERO CELL;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; NEURAMINIDASE; VERO CELLS; YOUNG ADULT;

EID: 84555178404     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir711     Document Type: Article

References (43)

1. World Health Organization (WHO). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/ disease/avian-influenza/country/cases-table-2011-04-21/en/index.html. Accessed 23 May 2011.
2. Kistner O, Howard MK, Spruth M, et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007; 25:6028-36. (Pubitemid 47077543)
3. Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 2008; 389:569-77. (Pubitemid 351874194)
4. Sabarth N, Howard MK, Savidis-Dacho H, van MA, Barrett PN, Kistner O. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 2010; 28:650-6.
5. Ehrlich HJ, Muller M, Fritsch S, et al. A cell culture (Vero)-derivedH5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009; 200:1113-8.
6. EhrlichHJ, Muller M, Oh HM, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573-84. (Pubitemid 351831358)
7. Schild GC, Oxford JS, Virelizier JL. Immunity to influenza. Dev Biol Stand 1975; 28:253-72.
8. Kilbourne ED, Laver WG, Schulman JL, Webster RG. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 1968; 2:281-8.
9. Jahiel RI, Kilbourne ED. Reduction in plaque size and reduction in plaque number as differing indices of influenza virus-antibody reactions. J Bacteriol 1966; 92:1521-34.
10. Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989; 63:1239-46. (Pubitemid 19061366)
11. Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993; 11:1037-9. (Pubitemid 23304001)
12. Johansson BE, Matthews JT, Kilbourne ED. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998; 16: 1009-15. (Pubitemid 28276016)
13. Johansson BE, Brett IC. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. Hum Vaccin 2008; 4:420-4.
14. Brett IC, Johansson BE. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005; 339: 273-80. (Pubitemid 41169794)
15. Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968; 2:778-86.
16. Murphy BR, Kasel JA, Chanock RM. Association of serum antineuraminidase antibody with resistance to influenza inman. N Engl JMed 1972; 286:1329-32.
17. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24:157-60. (Pubitemid 16090261)
18. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974; 129:411-20.
19. Murphy BR, Markoff LJ, Hosier NT, et al. Temperature-sensitive mutants of influenza A virus: evaluation of A/Victoria/3/75-ts-1[E] recombinant viruses in volunteers. Infect Immun 1978; 20:671-7. (Pubitemid 8352003)
20. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973; 1:623-5.
21. Beutner KR, Rizzone C, DeMello S, Ogra PL. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children. Dev Biol Stand 1976; 33:162-70.
22. Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 1979; 140:844-50. (Pubitemid 10165121)
23. Kilbourne ED, Johansson BE, Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci USA 1990; 87:786-90.
24. European Medicines Agency (EMEA). Guideline for dossier structure and content for pandemic influenza vaccine marketing authorisation application. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 10/WC500003993.pdf. Accessed 23 May 2011.
25. Powers DC, Kilbourne ED, Johansson BE. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol 1996; 3:511-6. (Pubitemid 26326275)
26. Marcelin G, Bland HM, Negovetich NJ, et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J Infect Dis 2010; 202:1634-8.
27. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr, Ogra PL. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol 1987; 138:3010-3. (Pubitemid 17072785)
28. Kilbourne ED, Couch RB, Kasel JA, et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995; 13:1799-803. (Pubitemid 26010054)
29. Hassantoufighi A, Zhang H, Sandbulte M, et al. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 2010; 28:790-7.
30. Lambre CR, Terzidis H, Greffard A, Webster RG. Measurement of antiinfluenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990; 135:49-57.
31. Lambre CR, Terzidis H, Greffard A, Webster RG. An enzyme-linked lectin assay for sialidase. Clin Chim Acta 1991; 198:183-93.
32. Sandbulte MR, Gao J, Straight TM, Eichelberger MC. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respi Viruses 2009; 3:233-40.
33. Cate TR, Rayford Y, Nino D, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28:2076-9.
34. Sultana I, Gao J, Markoff L, Eichelberger MC. Influenza neuraminidaseinhibiting antibodies are induced in the presence of zanamivir. Vaccine 2011; 29:2601-6.
35. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998; 16:960-8. (Pubitemid 28276008)
36. Webster RG, Krauss S. WHO manual on animal influenza diagnosis and surveillance. http://www.who.int/csr/resources/publications/influenza/ whocdscsrncs 20025rev.pdf. Accessed 23 May 2011.
37. Kendal AP, Noble GR, DowdleWR. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J Infect Dis 1977; 136(Suppl):S415-24. (Pubitemid 8293882)
38. Kendal AP, Bozeman FM, Ennis FA. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect Immun 1980; 29:966-71. (Pubitemid 10009299)
39. Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J Immunol 1987; 139: 2010-4. (Pubitemid 17141638)
40. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl JMed 2006; 354:1343-51.
41. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:e59.
42. Kilbourne ED. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J Infect Dis 1976; 134:384-94.
43. Tanimoto T, Nakatsu R, Fuke I, et al. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine 2005; 23:4598-609. (Pubitemid 41033375)